In this exciting era of ''next-gen cytogenetics,'' integrating genomic sequencing into the prenatal diagnostic setting is possible within an actionable time frame and can provide precise delineation of balanced chromosomal rearrangements at the nucleotide level. Given the increased risk of congenital abnormalities in newborns with de novo balanced chromosomal rearrangements, comprehensive interpretation of breakpoints could substantially improve prediction of phenotypic outcomes and support perinatal medical care. Herein, we present and evaluate sequencing results of balanced chromosomal rearrangements in ten prenatal subjects with respect to the location of regulatory chromatin domains (topologically associated domains [TADs]). The genomic material from all subjects was interpreted to be ''normal'' by microarray analyses, and their rearrangements would not have been detected by cell-free DNA (cfDNA) screening. The findings of our systematic approach correlate with phenotypes of both pregnancies with untoward outcomes (5/10) and with healthy newborns (3/10). Two pregnancies, one with a chromosomal aberration predicted to be of unknown clinical significance and another one predicted to be likely benign, were terminated prior to phenotype-genotype correlation (2/10). We demonstrate that the clinical interpretation of structural rearrangements should not be limited to interruption, deletion, or duplication of specific genes and should also incorporate regulatory domains of the human genome with critical ramifications for the control of gene expression. As detailed in this study, our molecular approach to both detecting and interpreting the breakpoints of structural rearrangements yields unparalleled information in comparison to other commonly used first-tier diagnostic methods, such as non-invasive cfDNA screening and microarray analysis, to provide improved genetic counseling for phenotypic outcome in the prenatal setting.
Introduction
Fetal material obtained through invasive methods can be assessed routinely with different techniques, including karyotyping, fluorescence in situ hybridization, and chromosomal microarray analysis (CMA). [1] [2] [3] Although karyotyping remains the principal cytogenetic tool in prenatal diagnosis, CMA has the advantage of higher resolution and is the preferred method in a fetus with one or more major structural abnormalities identified by ultrasonography. 1 However, unlike karyotyping, CMA cannot detect balanced chromosomal rearrangements, such as translocations, inversions, and insertions. The risk of congenital abnormalities is two to three times higher in newborns with apparently balanced de novo chromosomal rearrangements (6.1% for translocations and 9.4% for inversions) than in a population of pregnancies tested by amniocentesis. 4 The cause of the increase in abnormal phenotypes in such cases can be a submicroscopic deletion, duplication, disruption, dysregulation, or fusion of a gene(s) located at or near the breakpoints. Studies using CMA have demonstrated the presence of a cryptic imbalance in 40%-50% of subjects with an abnormal phenotype and an apparently balanced chromosomal rearrangement. [5] [6] [7] [8] [9] [10] [11] [12] Massively parallel sequencing technologies can provide timely localization of chromosomal breakpoints with nucleotide-level precision in all apparently balanced rearrangements, along with information on the gain or loss of genomic material, 13, 14 which could substantially improve the prediction of phenotypic outcomes and support perinatal medical care.
Outcomes of structural rearrangements changing the copy number of a gene or directly disrupting a gene can be predicted from dosage effects. However, if a balanced rearrangement occurs in a non-coding region or the regulatory effect of the rearrangement is more pertinent to an abnormal phenotype than the directly affected gene, predicting pathogenic consequences can become challenging and even erroneous when only the gene(s) with copy-number changes or disrupted gene(s) are evaluated. This is particularly important in prenatal diagnosis, because for many key developmental genes, cis-regulatory elements can extend beyond the transcription unit with an estimated median regulatortarget gene distance of 120 kb, 15 which can range up to 1.5 Mb. 16, 17 Topologically associated domains (TADs) have been elucidated as key elements of mammalian regulatory organization. 18, 19 TADs are highly conserved megabase-sized genomic segments that partition the genome into large units with frequent intra-domain interactions. They are separated by topological boundary regions (TBRs), which represent ''genomic insulators'' by blocking the interactions between adjacent TADs. Disruption of TBRs by structural rearrangements has been demonstrated to cause rewiring of genomic regulators in the WNT6-IHH-EPHA4-PAX3 locus (MIM: 604663, 600726, 602188, and 606597) and result in human limb malformations, as described by Lupiãnez et al. (Table 1 and Figure 1 ). 20 In this context, the developmental genes with historically well-known long-range regulation can be re-evaluated in relation to their TAD and TBR annotations ( Table 2 and Figure 1 ). For example, disruption of PAX6 (MIM: 607108) and regulatory elements located in the same TAD as PAX6 (up to 150 kb downstream) results in isolated aniridia, 21 whereas haploinsufficiency of WT1 (MIM: 194070), which is located in the TAD adjacent to PAX6, causes genitourinary anomalies without aniridia. 23 Deletions of the contiguous locus containing both PAX6 and WT1, including the TBR between their two adjacent TADs, result in the autosomal-dominant WAGR syndrome (MIM: 194072) with both aniridia and genitourinary anomalies, supporting the ''genomic insulator'' role of TBRs. In addition, the size of an individual TAD can be relevant to the extent of long-range regulation. TWIST1 (MIM: 601622) is known to have long-range regulation up to 260 kb downstream, which is located within the same 440 kb TAD as TWIST1.
Monoallelic disruption of both TWIST1 and its downstream regulatory region results in Saethre-Chotzen syndrome (MIM: 101400). 24 SOX9 (MIM: 608160) is reported to have long-range regulation up to 1.5 Mb upstream, which is located within the same 1.88 Mb TAD as SOX9. Monoallelic disruption of both SOX9 and its regulatory region is associated with campomelic dysplasia (MIM: 114290) and Pierre Robin sequence (MIM: 261800). 25, 28, 29 There might also be phenotype-specific regulators within the same TAD for a developmental gene depending on their distance from the gene of interest. Monoallelic disruption of regulatory elements located within the same 1.6 Mb TAD as SHH (MIM: 600725) can result in type 3 holoprosencephaly (MIM: 142945) or preaxial polydactyly (MIM: 174500), depending on the location (265 kb upstream or 1 Mb upstream of SHH, respectively). 26 Lastly, in addition to the genes showing a phenotype with monoallelic disruption, regulatory regions of developmental genes located on the X chromosome or imprinted genes should also be carefully analyzed, given that disruption of a single allele through balanced rearrangements could result in an abnormal phenotype in such cases. For instance, POU3F4 (MIM: 300039) is an X-linked recessively inherited gene with long-range regulation up to 900 kb upstream 27 in a 3.04 Mb TAD, and disruption of a single allele of POU3F4 or its regulatory region results in deafness in males. Overall, advances in the understanding of chromatin organization of the human genome, along with the evolving databases of phenotypes associated with structural variation, could provide a conceptual framework for the interpretation of balanced-rearrangement breakpoints and their potential cis-regulatory effects.
Identifying breakpoints of balanced chromosomal rearrangements has been the foundation of the Developmental Genome Anatomy Project (DGAP), which has sequenced more than 200 subjects. As an extension of these efforts, in this study, we sequenced ten prenatal subjects with balanced chromosomal rearrangements by using customized large-insert libraries and used publicly available databases to interpret the breakpoints on the basis of convergent genomic evidence in light of previously annotated TADs and TBRs in human embryonic stem cells. 29 
Material and Methods

Subjects
Ten subjects were enrolled after proper informed consent was acquired in accordance with an institutional-review-board protocol approved by Partners HealthCare System in Boston. These ten subjects represent the total of a consecutive series of DGAP prenatal referrals to date, and prior to enrollment, all had balanced chromosomal rearrangements according to karyotyping with normal CMA results. Two subjects (DGAP239 and DGAP259) have been reported in part previously.
30,31
Sequencing and Bioinformatic Analysis
Genomic DNA was extracted from amniocytes or chorionic villi with a Gentra Puregene Cell Kit (QIAGEN). Large-insert structural-variation sequencing was performed as previously described. 12, 26 In brief, after the production of large-insert libraries (target size of 2-3.5 kb) and quality control, massively parallel paired-end sequencing of 25 or 50 cycles was performed with an Illumina HiSeq 2000 or 2500. Reads were processed with our customized structural-variant sequencing pipelines, which include alignment, clustering of anomalous read pairs, extensive cluster filtering, and variant screening against known structural variants. [32] [33] [34] [35] Genome-wide physical coverage of inserts ranged from 353 to 683, and DNA input ranged from 900 ng to 5 mg. For all subjects with sufficient material, DNA was amplified by PCR with primers based on sequence reads supporting the rearrangement junction for confirmation of breakpoints.
Analysis of Convergent Genomic Evidence
In addition to genes located directly at breakpoints, phenotypic associations were evaluated in relation to previously annotated TADs and TBRs in human embryonic stem cells 18 for positional effects on protein-coding genes through disruption of potential regulatory elements. DECIPHER was utilized for predicting the probability of haploinsufficiency, which was determined on the basis of genes known to produce a phenotype through haploinsufficiency and genes disrupted by unambiguous loss-of-function variants in at least two apparently healthy individuals. Low haploinsufficiency indices (<10%) indicate a high predicted probability that a gene will exhibit haploinsufficiency (i.e., disruption of one allele might be pathogenic, also referred to as monoallelic). 36 Within the analyzed intervals, disrupted genes, genes with a haploinsufficiency index < 10%, hemizygous or imprinted genes, and genes associated with a phenotype were evaluated in detail for each subject in relation to the disrupted TADs and TBRs. Abnormal phenotypic associations of disrupted or dysregulated regions were reviewed in the scientific literature, OMIM, 37 OMIM Gene Map and Morbid Map, 37 DECIPHER, 38 and the Developmental Disorders Genotype-to-Phenotype (DDG2P) database. 39 
Expression Studies
qRT-PCR was performed with RNA extracted from cultured prenatal cells of the available subjects (amniocytes from DGAP247 and chorionic villi from DGAP248 and DGAP288) and control samples (amniocytes or chorionic villi with a normal karyotype referred for advanced maternal age) or cord blood (DGAP247 and DGAP288). qRT-PCR was performed according to standard conditions of the CFX Real-Time PCR Detection System (Bio-Rad), and transcription levels were quantified with the DDCT method. 30 
Results
Prior to enrollment, karyotyping was performed for all pregnancies because they were considered to be high risk (e.g., advanced maternal age, abnormal first-trimester serum screening, and/or ultrasound abnormality) with normal CMA results during clinical assessment (see Supplemental Note). Among the ten subjects analyzed, four had reciprocal translocations, five had inversions, and one had a complex rearrangement according to karyotyping. Sequencing revised the initial karyotype by providing nucleotide-level resolution to the initially described chromosome bands with a size ranging from 2.8 to 53.6 Mb, encompassing 63-1,032 genes and 16-358 phenotypeassociated loci for each rearrangement (Table 3 and Table  S1 ). 40 In addition to refining breakpoints, including those in a subject with a very complex karyotype (DGAP259), sequencing revealed cryptic rearrangements unapparent by karyotyping in four subjects (DGAP258, DGAP268, DGAP290, and DGAP295). All rearrangements were located within a TAD, except for one that was located in a TBR at Xq28 (DGAP285) (Figures 2, 3 , and 4; Tables 4,  5 , and 6; and Table S2 ). Five subjects had abnormal clinical outcomes, three continue to be healthy, and two were terminated prior to detection of any potential abnormal findings (Table 7) . Figure 2A and Table 4 ). Whereas biallelic losses of LMBRD1 are associated with methylmalonic aciduria and homocystinuria, cblF type (MIM: 277380) (no phenotypic overlap with DGAP239), 42 monoallelic loss of CHD7 is well known to be associated with CHARGE syndrome (it is mutated in more than 90% of subjects), correlating with the low haploinsufficiency index of CHD7 and the clinical outcome of DGAP239 (see Supplemental Note and Tables S3 and S4 ). Abbreviations are as follows: hESC, human embryonic stem cell; HPE3, holoprosencephaly type 3; TAD, topologically associated domain; TBR, topological boundary region; and WAGR, Wilms tumor, aniridia, genitourinary anomalies, and mental retardation. Figure 1C ). The 2p12 breakpoint is located within a TAD that includes LRRTM4 (MIM: 610870), a gene with a low haploinsufficiency index and no reported abnormal phenotypic association. However, structure and expression profiles of LRRTM mRNAs in mice suggest a role in development and maintenance of the vertebrate nervous system. 44 RFC3 has a low haploinsufficiency index and showed decreased RNA expression in the prenatal sample ( Figure S3 ). 36 In addition, NBEA (MIM: 6084889), a candidate autism gene with a low haploinsufficiency score, 45, 46 is located within the same 2.16 Mb TAD and 973 kb downstream of the breakpoints ( Figure 2C and Table 4 ). Given the presence of two genes with low haploinsufficiency indices-one associated with a phenotype and located within the 13q13.2 rearrangement TAD (NBEA) and the other implicated in nervous system development and located within the 2p12 rearrangement TAD (LRRTM4)-but the lack of strong evidence for a phenotypic correlation, these results are interpreted as ''unknown clinical significance. Clinical follow-up was not possible because the pregnancy was terminated (see Supplemental Note and Tables S7 and S8 (6)(p23q13) by karyotyping) within non-genic regions at both 6p25.3 and 6q16.1. In addition, a paternally inherited cryptic non-genic rearrangement at 6q15 was detected ( Figure 2D and Table 4 ). Because of the length of the sequencing reads, it was not possible to determine whether both of the breakpoints on 6q reside in the same paternally inherited chromosome; however, given their relative proximity and localization within the same 2. Figure 4A and Table 6 ). CPEB3 does not have a low haploinsufficiency index and does not have any abnormal phenotypic association. Analysis of protein-coding genes localized in the same TAD as the breakpoints also did not reveal any genes associated with an abnormal phenotype, correlating with the normal clinical phenotype of DGAP268 (see Supplemental Note  and Tables S19-S21 ).
DGAP285
DGAP285 (46,Y,inv(X)(p11.2q28).arr(1-22)x2,(XY)x1.seq [GRCh37/hg19] inv(X)(p11.21q28)) showed abnormal prenatal imaging findings, including hydrocephalus, starting at 22.5 weeks and fetal demise at 31.4 weeks after decreased fetal movements. Sequencing of the prenatal DNA sample identified inversion breakpoints (designated as inv(X)(p11.2q28) by karyotyping) disrupting FAM104B at Xp11.21 and within a non-genic region at Xq28 ( Figure 4B and Table 6 ). Breakpoints at Xq28 disrupt a TBR, which could result in genomic rewiring of the surrounding TADs and TBRs. MTM1 (MIM: 300415) is an X-linked recessively inherited gene associated with centronuclear myopathy (MIM: 310400), a prenatalonset fatal disease with clinical findings including decreased fetal movements, hydrocephalus, and stillbirth. [73] [74] [75] MTM1 is located in a TBR upstream of the TBR at the Xq28 rearrangement, and therefore dysregulation of MTM1 might contribute to the phenotype of DGAP285 (see Supplemental Note and Tables S22  and S23 ).
DGAP288
DGAP288 (46,XX,t(6;17)(q13;q21)dn.arr(1-22,X)x2.seq [GRCh37/hg19] t(6;17)(q21;q24.3)dn) had cystic hygroma at 11.1 weeks, followed by prenatal imaging findings consistent with Pierre Robin sequence, which were confirmed during the postnatal period. Sequencing of the prenatal DNA sample identified translocation breakpoints (designated as t(6;17)(q13;q21) by karyotyping) within non-genic regions at 6q21 and 17q24.3 ( Figure 4C and Table 6 ). Breakpoints at 17q24.3 were in a 1.88 Mb TAD corresponding to an upstream cis-regulatory region of SOX9 (MIM: 608160), a region known to be associated with Pierre Robin sequence as a result of dysregulation of SOX9, an autosomal-dominantly inherited gene with a low haploinsufficiency index. 25, 28, 29 The prenatal sample showed decreased RNA expression of SOX9 ( Figure 5 ), correlating with the clinical outcome of DGAP288 (see Supplemental Note and Tables S24 and S25 ). DGAP290 DGAP290 (46,XY,t(2;7)(q33;q32)dn.arr(1-22)x2,(XY)x1. seq[GRCh37/hg19](2,7)cx,der(2)t(2;7)(q32.3;q33)inv(7) (q33q33)dn,der(7)t(2;7)dn) was a high-risk pregnancy according to first-trimester screening, which showed normal imaging up to 18 weeks. The parents decided to terminate the pregnancy at 23 weeks because of uncertainty of the clinical significance of the balanced rearrangement. Sequencing of the prenatal DNA sample identified translocation breakpoints (designated as t(2;7)(q33;q32) by karyotyping) disrupting HECW2 at 2q32.3 and NUP205 Although not located within the same hESC TAD 18 as the breakpoint, these genes might be relevant to the phenotype of DGAP259 given the complexity of the rearrangement.
The American Journal of Human Genetics 99, 1-19, November 3, 2016 11
(MIM: 614352) at 7q33 and an additional non-genic disruption at 7q33 ( Figure 4D and Table 6 ). Neither disrupted gene had a low haploinsufficiency index, and analysis of proteincoding genes in the same TAD as the breakpoints did not reveal any genes associated with an abnormal phenotype. These results are interpreted as ''unknown clinical significance, likely to be benign''; however, clinical correlation was not possible because the pregnancy was terminated (see Supplemental Note and Tables S26 and S27 ).
DGAP295
DGAP295 (46,XY,t(2;11)(p13.1;p15.5)dn.arr(1-22)x2,(XY) x1.seq[GRCh37/hg19](2,11)cx,der(2)inv(11)(p15.5)inv(11) (p15.5)t(2;11)(p13.3;p15.5)dn,der(11)t(2;11)dn) had abnormal first-trimester screening, which showed an abnormal prenatal imaging finding of growth restriction starting from 19 weeks, and weighed 450 g upon delivery at 31 weeks. Sequencing of the prenatal DNA sample identified translocation breakpoints (designated as t(2;11)(p13.1;p15.5) by karyotyping) disrupting GFPT1 (MIM: 138292) at 2p13.3 and multiple non-genic regions at 11p15.5 within a 70 kb distribution ( Figure 4E and Table 6 ). The complex breakpoints at 11p15.5 are within the same 600 kb TAD as IGF2 (MIM: 147470), an imprinted region known to be associated with growth restriction with distinctive facies (GRDF [MIM: 616489]) 71 and SilverRussell syndrome (MIM: 180860), 72 consistent with the growth restricted phenotype of DGAP295 (see Supplemental Note and Tables S28 and S29 ).
Discussion
We report whole-genome sequencing of ten prenatal subjects with balanced chromosomal rearrangements with ''normal'' CMA results and their phenotypic interpretation through publicly available resources. Each subject has contributed uniquely to our experience in the evolution of this approach to a new standard of care in prenatal diagnosis by providing further insight into prognosis through incorporation of an understanding of the regulatory genome (Table 7 ). In the evaluation of the pathogenic outcomes of balanced rearrangements, disruption or dysregulation of a single allele is of particular significance when it involves a region known to be hemizygous for X-linked traits, haploinsufficient (autosomal dominant), or imprinted and associated with an abnormal phenotype. Next-generation sequencing can identify the disrupted regions at the nucleotide level; however, predicting the dysregulation of the genes in the vicinity of the breakpoints is more challenging. Advances in the understanding of large-scale regulatory chromatin domains (TADs) contribute to overcoming this obstacle. A recent study analyzing the WNT6-IHH-EPHA4-PAX3 locus and three related congenital genetic disorders has provided multiple layers of evidence for the significance of these megabase-sized regulatory domains and their contribution to abnormal phenotypes through genomic rewiring of the regulatory boundaries resulting from structural rearrangements. 20 It is well established that the cis-regulatory elements for many key developmental genes can extend beyond the transcription unit in the range of 120 kb to 1.5 Mb, [15] [16] [17] 76, 77 which could be explained by these regulatory associations. Therefore, we analyzed the aforementioned characteristics (hemizygosity, haploinsufficiency, and imprinting) of the disrupted genes at the breakpoints, as well as the protein-coding genes located in the regulatory domains and boundaries (TADs and TBRs, respectively) associated with the breakpoints to identify the dysregulated regions. Then, we evaluated the phenotypic and developmental significance of these genes of interest. None of the three subjects with normal outcomes (DGAP247, DGAP258, and DGAP268) had disrupted genes or were predicted to have dysregulated genes involved with an abnormal phenotype. Among five subjects with abnormal outcomes, one (DGAP239) had a disrupted syndromic gene with a low haploinsufficiency index, one (DGAP285) had a disrupted TBR and was predicted to have a dysregulated X-linked recessively inherited syndromic gene, one (DGAP288) had a dysregulated gene involved with an abnormal phenotype, one (DGAP295) was predicted to have a dysregulated imprinted gene involved with a syndrome, and lastly, in one chromothripsis-affected subject (DGAP259), multiple genes associated with CNS malformations and genomic organization were disrupted and predicted to be dysregulated. All showed abnormal phenotypes overlapping the predicted outcomes of the sequencing results. Of note, two of the five subjects with abnormal phenotypes (DGAP239 and DGAP295) had additional disrupted genes involved in autosomal-recessive syndromes and did not show any clinical features associated with these syndromes. However, in such cases, a potential ''carrier'' status for the relevant syndromes might be considered in future genetic counseling of the newborn if the outcome is otherwise normal. Among the two terminated pregnancies without any abnormal phenotypes prior to termination, one subject (DGAP248) is interpreted as having a rearrangement predicted to be of unknown clinical significance, and the other (DGAP290) is interpreted has having a rearrangement predicted to be likely benign.
Although karyotyping remains the standard of care for prenatal diagnosis, advances in genomic technologies are rapidly transitioning into clinical practice. Non-invasive cfDNA screening and CMA in invasive testing are increasingly popular methods in the field of prenatal genetics. [78] [79] [80] karyotype) if the prenatal diagnostic test is performed for an indication of a structural abnormality detected by prenatal imaging studies. 33 Nonetheless, CMA cannot assess balanced rearrangements and, if performed alone in the present study, would have ''missed'' all five prenatal subjects with abnormal outcomes (each of whom had abnormal prenatal imaging findings), including a subject with complex chromothripsis (DGAP259). Karyotyping remains superior to CMA for the detection of balanced rearrangements, despite its megabase-sized resolution. Next-generation sequencing using large-insert libraries provides precise delineation of the breakpoints of structural rearrangements while detecting additional high-resolution cryptic rearrangements, as well as copynumber alterations that could potentially be detected by CMA and not karyotyping. Although cfDNA screening is also a sequence-based approach, given the fragmented nature of cell-free DNA, it would be cumbersome to analyze truly balanced rearrangements with the current cfDNA technology. Another sequence-based approach in the field of prenatal genetics is whole-exome sequencing. 82, 83 Although this method provides higher nucleotide-level coverage and therefore can more reliably detect nucleotide-level mutations in the exome than our large-insert library method, given the presence of non-genic breakpoints in structural rearrangements, a whole-genome paired-end sequencing approach using large-insert libraries, as presented herein, would be most useful in detecting structural rearrangements. Currently, we would recommend using this method in subjects with a normal CMA and a karyotype with a balanced rearrangement (the order of CMA and karyotyping depends on the clinical scenario). In subjects with an abnormal CMA and/or a karyotype without a balanced rearrangement that fails to explain an abnormal phenotype, our method could still be valuable for identifying cryptic rearrangements in the appropriate clinical setting. We believe next-generation sequencing technologies will eventually be proposed as a first-line diagnostic method because they can provide details on structural rearrangements that cannot be detected by either karyotyping or CMA.
As with other genomic testing methods, whole-genome sequencing also raises the issue of variants of unknown clinical significance. The topic of ''unknown clinical significance'' is not a new problem for the field of prenatal diagnosis, whether it be a subtle imaging finding such as mildly enlarged ventricles or the detection of a balanced chromosomal rearrangement by karyotyping. Sequencing provides additional understanding of the breakpoints involved in a balanced chromosomal rearrangement. Although this information could fundamentally influence genetic counseling, clinical management, and decision making, it could also bring additional pressure to managing unknown findings on the basis of current genomic evidence. Eventually, evolving annotation of the human genome-including the discovery of disease-associated genes or other predictors of regulatory effect, such as pathogenic increases in gene expression-along with guidelines from expert committees, could close these gaps of interpretation, as has been the case with improved clinical reporting of CMA results over the past decade. 84 In conclusion, detecting balanced chromosomal rearrangements with whole-genome sequencing provides nucleotide-level precision incomparable to currently employed prenatal genetic-testing methods, thus enabling the regulatory genome to be evaluated in such a way that could prove invaluable in clinical interpretation.
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